Press Releases

Press Releases

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

As of the March 11, 2022 data cut-off date, 16 patients in 7 dosing cohorts with different types of progressing cancer received ANV419 every 14 days. ANV419, administered intravenously over 15 minutes was exceptionally well tolerated with most patients experiencing a mild Grade 1 infusion-related reaction with chills and low-grade fever a few hours after dosing, which resolved with antipyretic treatment. No patients experienced a Grade 3 or worse drug related AE and no patients have withdrawn from study due to AEs. No dose limiting toxicities have been observed.
read more
Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022

Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022

Anaveon, a clinical-stage immuno-oncology company, today announced that it will present first clinical data from the ongoing Phase I/II study of ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors, in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisana, April 8 to April 13, 2022.
read more
Anaveon to raise CHF 110 million in oversubscribed Series B financing

Anaveon to raise CHF 110 million in oversubscribed Series B financing

Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax.
read more